• LAST PRICE
    0.7201
  • TODAY'S CHANGE (%)
    Trending Up0.0200 (2.8567%)
  • Bid / Lots
    0.7000/ 8
  • Ask / Lots
    0.7600/ 10
  • Open / Previous Close
    0.7001 / 0.7001
  • Day Range
    Low 0.7000
    High 0.7400
  • 52 Week Range
    Low 0.5900
    High 2.9400
  • Volume
    22,122
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.7001
TimeVolumeANGN
09:37 ET17000.7001
10:13 ET11000.71
11:02 ET5730.7
11:39 ET22000.7399
11:43 ET5000.74
11:45 ET5770.7001
12:24 ET17980.7001
03:06 ET42000.73
03:12 ET56260.7001
03:15 ET6000.7
03:19 ET4000.7158
03:26 ET8130.7079
03:44 ET2250.7
03:57 ET3460.7111
04:00 ET3590.7201
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANGN
Angion Biomedica Corp
21.1M
-1.2x
---
United StatesSQZ
SQZ Biotechnologies Co
24.4M
-0.3x
---
United StatesCASI
CASI Pharmaceuticals Inc
28.3M
-1.0x
---
United StatesNBRV
Nabriva Therapeutics PLC
4.7M
-0.1x
---
United StatesCDAK
Codiak BioSciences, Inc.
25.3M
-1.0x
---
United StatesEMMA
Emmaus Life Sciences Inc
20.8M
-1.1x
---
As of 2023-01-31

Company Information

Angion Biomedica Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company’s products include ANG-3070, ROCK2 Inhibitor, CYP11B2 Inhibitor and ANG-3777. ANG-3070 is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. The Company provides ANG-3070 for Fibrotic Diseases; ANG-3070 for Renal Fibrosis; ANG-3070 for Pulmonary Fibrosis. ROCK2 Inhibitor program targeted towards the treatment of fibrotic diseases. CYP11B2 Inhibitor program targeted towards diseases related to aldosterone synthase dysregulation. ANG-3777 is designed to mimic the biological activity of HGF and to treat acute organ injuries, such as delayed graft function.

Contact Information

Headquarters
51 Charles Lindbergh BoulevardUNIONDALE, NY, United States 11553
Phone
415-655-4899
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Jay Venkatesan
Chairman Emeritus, Director
Itzhak Goldberg
Chief Financial Officer
Gregory Curhan
Executive Vice President, Chief Business Officer, Chief Compliance Officer, General Counsel, Corporate Secretary
Jennifer Rhodes
Lead Independent Director
Victor Ganzi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$21.1M
Revenue (TTM)
$28.2M
Shares Outstanding
30.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.58
Book Value
$2.72
P/E Ratio
-1.2x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-63.51%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.